Arcutis Biotherapeutics Statistics
Total Valuation
ARQT has a market cap or net worth of $1.00 billion. The enterprise value is $937.98 million.
| Market Cap | 1.00B |
| Enterprise Value | 937.98M |
Important Dates
The next estimated earnings date is Tuesday, May 7, 2024, after market close.
| Earnings Date | May 7, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
ARQT has 114.97 million shares outstanding. The number of shares has increased by 25.94% in one year.
| Shares Outstanding | 114.97M |
| Shares Change (YoY) | +25.94% |
| Shares Change (QoQ) | +12.28% |
| Owned by Insiders (%) | 2.50% |
| Owned by Institutions (%) | 96.20% |
| Float | 74.79M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 16.86 |
| Forward PS | 9.47 |
| PB Ratio | 11.33 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | 15.74 |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 7.08, with a Debt / Equity ratio of 2.32.
| Current Ratio | 7.08 |
| Quick Ratio | 6.40 |
| Debt / Equity | 2.32 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -7.72 |
Financial Efficiency
Return on equity (ROE) is -294.90% and return on invested capital (ROIC) is -81.84%.
| Return on Equity (ROE) | -294.90% |
| Return on Assets (ROA) | -78.60% |
| Return on Capital (ROIC) | -81.84% |
| Revenue Per Employee | $201,372 |
| Profits Per Employee | -$885,608 |
| Employee Count | 296 |
| Asset Turnover | 0.18 |
| Inventory Turnover | 0.48 |
Taxes
In the past 12 months, ARQT has paid $3.11 million in taxes.
| Income Tax | 3.11M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -34.19% in the last 52 weeks. The beta is 1.14, so ARQT's price volatility has been higher than the market average.
| Beta (1Y) | 1.14 |
| 52-Week Price Change | -34.19% |
| 50-Day Moving Average | 10.03 |
| 200-Day Moving Average | 6.51 |
| Relative Strength Index (RSI) | 38.46 |
| Average Volume (30 Days) | 4,576,062 |
Short Selling Information
The latest short interest is 19.26 million, so 16.75% of the outstanding shares have been sold short.
| Short Interest | 19.26M |
| Short Previous Month | 14.99M |
| Short % of Shares Out | 16.75% |
| Short % of Float | 25.75% |
| Short Ratio (days to cover) | 4.27 |
Income Statement
In the last 12 months, ARQT had revenue of $59.61 million and -$262.14 million in losses. Loss per share was -$3.78.
| Revenue | 59.61M |
| Gross Profit | 54.62M |
| Operating Income | -241.10M |
| Pretax Income | -259.03M |
| Net Income | -262.14M |
| EBITDA | -227.43M |
| EBIT | -229.32M |
| Loss Per Share | -$3.78 |
Balance Sheet
The company has $272.79 million in cash and $205.92 million in debt, giving a net cash position of $66.87 million or $0.58 per share.
| Cash & Cash Equivalents | 272.79M |
| Total Debt | 205.92M |
| Net Cash | 66.87M |
| Net Cash Per Share | $0.58 |
| Equity / Book Value | 88.67M |
| Book Value Per Share | 0.77 |
| Working Capital | 283.76M |
Cash Flow
In the last 12 months, operating cash flow was -$247.06 million and capital expenditures -$428,000, giving a free cash flow of -$247.49 million.
| Operating Cash Flow | -247.06M |
| Capital Expenditures | -428,000 |
| Free Cash Flow | -247.49M |
| FCF Per Share | -$3.57 |
Margins
Gross margin is 91.63%, with operating and profit margins of -404.49% and -439.79%.
| Gross Margin | 91.63% |
| Operating Margin | -404.49% |
| Pretax Margin | -434.57% |
| Profit Margin | -439.79% |
| EBITDA Margin | -381.56% |
| EBIT Margin | -384.72% |
| FCF Margin | -415.20% |
Dividends & Yields
ARQT does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -25.94% |
| Shareholder Yield | -25.94% |
| Earnings Yield | -26.09% |
| FCF Yield | -24.63% |
Analyst Forecast
The average price target for ARQT is $27.71, which is 217.05% higher than the current price. The consensus rating is "Buy".
| Price Target | $27.71 |
| Price Target Difference | 217.05% |
| Analyst Consensus | Buy |
| Analyst Count | 8 |
| Revenue Growth Forecast (5Y) | 62.89% |
| EPS Growth Forecast (5Y) | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
ARQT has an Altman Z-Score of -2.69 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -2.69 |
| Piotroski F-Score | 3 |